Your browser doesn't support javascript.
loading
Addition of Losartan to FOLFIRINOX and Chemoradiation Reduces Immunosuppression-Associated Genes, Tregs, and FOXP3+ Cancer Cells in Locally Advanced Pancreatic Cancer.
Boucher, Yves; Posada, Jessica M; Subudhi, Sonu; Kumar, Ashwin S; Rosario, Spencer R; Gu, Liqun; Kumra, Heena; Mino-Kenudson, Mari; Talele, Nilesh P; Duda, Dan G; Fukumura, Dai; Wo, Jennifer Y; Clark, Jeffrey W; Ryan, David P; Fernandez-Del Castillo, Carlos; Hong, Theodore S; Pittet, Mikael J; Jain, Rakesh K.
Affiliation
  • Boucher Y; Steele Laboratories of Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
  • Posada JM; Steele Laboratories of Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
  • Subudhi S; Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts.
  • Kumar AS; Steele Laboratories of Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
  • Rosario SR; Steele Laboratories of Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
  • Gu L; Harvard-MIT Division of Health Sciences and Technology, Cambridge, Massachusetts.
  • Kumra H; Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, New York.
  • Mino-Kenudson M; Department of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, New York.
  • Talele NP; Steele Laboratories of Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
  • Duda DG; Steele Laboratories of Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
  • Fukumura D; Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
  • Wo JY; Steele Laboratories of Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
  • Clark JW; Steele Laboratories of Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
  • Ryan DP; Steele Laboratories of Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
  • Fernandez-Del Castillo C; Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
  • Hong TS; Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
  • Pittet MJ; Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
  • Jain RK; Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
Clin Cancer Res ; 29(8): 1605-1619, 2023 04 14.
Article in En | MEDLINE | ID: mdl-36749873
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pancreatic Neoplasms / Antineoplastic Combined Chemotherapy Protocols Type of study: Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Clin Cancer Res Journal subject: NEOPLASIAS Year: 2023 Document type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pancreatic Neoplasms / Antineoplastic Combined Chemotherapy Protocols Type of study: Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Clin Cancer Res Journal subject: NEOPLASIAS Year: 2023 Document type: Article